Parnassus Value Select ETF Q1 2026 Commentary

Parnassus Value Select ETF fell 1.45% for the quarter, underperforming the Russell 1000 Value Index by 3.55 percentage points, primarily due to no Energy exposure and holdings in Health Care and Financials. The fund described first-quarter volatility as elevated but said it remains positioned with a quality-oriented portfolio and balanced exposure across traditional value and secular themes. The update is mainly portfolio commentary rather than a broad market catalyst.

Analysis

The performance gap is less about style drift than about factor timing: a quality/value portfolio will usually lag when the market rewards cyclicality, commodity beta, and lower-quality balance-sheet leverage. If the current tape is being driven by a modest growth scare plus a rebound in real assets, the missing energy exposure is a feature of the portfolio construction problem, not just a sector call — it means the fund is implicitly short inflation persistence and long economic softening.

The more interesting second-order risk is inside Health Care and Financials. In health care, higher-volatility quarters typically punish any names with reimbursement, pipeline, or utilization ambiguity, while the market selectively pays up for balance-sheet strength and recurring demand; that creates dispersion large enough to make pair trades more attractive than outright sector bets. In financials, the weak point is not rates per se but credit sensitivity and deposit competition: if funding costs stay sticky for another 1-2 quarters, lenders with weaker core deposits or commercial real estate exposure can underperform even if the index stabilizes.

The contrarian view is that the underweight to energy may become a hidden advantage if oil prices roll over or if the market starts discounting slower global demand. Energy has a habit of becoming consensus just as earnings momentum peaks; if crude stalls, the earnings revisions cycle can reverse faster than investors expect, and the sector can give back performance in weeks rather than months. That makes the current underperformance potentially transitory rather than structural, especially if quality names regain leadership once volatility cools.

Catalyst-wise, watch the next 30-60 days for a rotation in factor leadership: if breadth narrows and defensives reassert, the portfolio should recapture relative performance through its quality bias. Conversely, if the rally broadens into cyclicals and commodity-linked value, the fund may need a tactical hedge rather than a wholesale style change. The key question is whether the current weakness is a one-quarter positioning unwind or the start of a longer regime shift toward inflation-sensitive value.

Key Decisions for Investors

• Add a tactical hedge to offset missing energy beta: buy XLE or XOP on a 4-8 week horizon, sized modestly, with a stop if crude weakens and the sector underperforms the market for two consecutive weeks.
• Use a pair trade within Financials: long BAC or JPM versus short a regional lender ETF such as KRE for 1-3 months, targeting deposit franchise resilience and lower credit sensitivity; exit if credit spreads tighten materially.
• In Health Care, favor quality over beta: long XLV or a basket of large-cap pharma/managed care names versus short higher-variance biotech exposure for 6-10 weeks, aiming to capture dispersion if volatility remains elevated.
• If the fund can express the view more directly, reduce outright underweight risk by buying short-dated calls on XLE rather than spot exposure, limiting downside if energy leadership fades quickly.
• Monitor relative performance of the quality factor versus cyclical value over the next month; if the gap persists, rotate incrementally into secular growers with durable free cash flow rather than chasing the highest-beta value names.